Evidence map›Paper›PMID 34160685›Full record

ArticleCancer immunology, immunotherapy : CII2022

T-cell responses and combined immunotherapy against human carbonic anhydrase 9-expressing mouse renal cell carcinoma.

Mamoru Harada, Yuichi Iida, Hitoshi Kotani, Takafumi Minami, Yoshihiro Komohara, Masatoshi Eto, Kazuhiro Yoshikawa, Hirotsugu Uemura

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Mamoru HaradaDepartment of Immunology, Shimane University Faculty of Medicine, Izumo, Shimane, 693-8501, Japan. haramamo@med.shimane-u.ac.jp.ORCID http://orcid.org/0000-0002-9737-0360
Yuichi IidaDepartment of Immunology, Shimane University Faculty of Medicine, Izumo, Shimane, 693-8501, Japan.
Hitoshi KotaniDepartment of Immunology, Shimane University Faculty of Medicine, Izumo, Shimane, 693-8501, Japan.
Takafumi MinamiDepartment of Urology, Kindai University Faculty of Medicine, Osaka, Japan.
Yoshihiro KomoharaDepartment of Cell Pathology, Graduate School of Medical Science, Kumamoto University, Kumamoto, Japan.
Masatoshi EtoDepartment of Urology, Graduate School of Medical Science, Kyushu University, Fukuoka, Japan.
Kazuhiro YoshikawaDivision of Research Creation and Biobank, Research Creation Support Center, Aichi Medical University, Aichi, Japan.
Hirotsugu UemuraDepartment of Urology, Kindai University Faculty of Medicine, Osaka, Japan.
Shimane University · JPKindai University · JPAichi Medical University · JPKumamoto University · JPKyushu University · JP

Funding

Japan Society for the Promotion of Science 17K07217Japan Society for the Promotion of Science 17K11301Japan Society for the Promotion of Science 19H03794
6 · The paper itself

Abstract

Renal cell carcinoma (RCC) is known to respond to immune checkpoint blockade (ICB) therapy, whereas there has been limited analysis of T-cell responses to RCC. In this study, we utilized human carbonic anhydrase 9 (hCA9) as a model neoantigen of mouse RENCA RCC. hCA9-expressing RENCA RCC (RENCA/hCA9) cells were rejected in young mice but grew in aged mice. CD8

Indexed as

AnimalsApoptosisCarbonic Anhydrase IXCarcinoma, Renal CellCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCell ProliferationFemaleHumansImmune Checkpoint InhibitorsImmunotherapyKidney NeoplasmsMiceMice, Inbred BALB CTumor Cells, CulturedXenograft Model Antitumor AssaysCarbonic Anhydrase IXImmune Checkpoint InhibitorsCarbonic anhydrase 9Combined immunotherapyImmune checkpoint blockadeNeoantigenRenal cell carcinoma

Identifiers

PMID34160685
PMCPMC10992521
OpenAlexW3174433092

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.